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Ethnopharmacological relevance: Rosemary, Rosmarinus ofﬁcinalis L., has several therapeutic applications
in folk medicine for the treatment of a wide range of diseases, including depression.
Aim of the study: To evaluate the ability of Rosmarinus ofﬁcinalis hydroalcoholic extract (ROHE), as
compared to the positive control ﬂuoxetine, to reverse behavioral (hyperactivity, anhedonic behavior and
learning deﬁcit in water maze) and biochemical alterations (serum glucose level and acetylcholinesterase,
AChE, activity) induced by an animal model of depression, the olfactory bulbectomy (OB) in mice.
Materials and methods: Locomotor and exploratory behavior was assessed in the open-ﬁeld, novel object
and novel cage tests, anhedonic behavior was assessed in the splash test; cognitive deﬁcits were
evaluated in the water maze task. For the ﬁrst set of experiments, ROHE (10–300 mg/kg) or ﬂuoxetine
(10 mg/kg) was administered once daily (p.o.) for 14 days after OB and the behavioral tests were
performed. For the second set of experiments, serum glucose and hippocampal and cerebrocortical AChE
activity were determined in OB and SHAM-operated mice treated orally with ROHE (10 mg/kg),
ﬂuoxetine (10 mg/kg) or vehicle.
Results: ROHE (10–300 mg/kg), similar to ﬂuoxetine, reversed OB-induced hyperactivity, increased explora-
tory and anhedonic behavior. OB needed signiﬁcantly more trials in the training session to acquire the spatial
information, but they displayed a similar proﬁle to that of SHAM mice in the test session
(24 h later), demonstrating a selective deﬁcit in spatial learning, which was not reversed by ROHE or
ﬂuoxetine. A reduced serum glucose level and an increased hippocampal AChE activity were observed in
bulbectomized mice; only the latter effect was reversed by ﬂuoxetine, while both effects were reversed
by ROHE.
Conclusions: ROHE exerted an antidepressant-like effect in bulbectomized mice and was able to abolish AchE
alterations and hypoglycemia, but not spatial learning deﬁcit induced by OB. Overall, results suggest the
potential of Rosmarinus ofﬁcinalis for the treatment of depression, validating the traditional use of this plant.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
According to the World Health Organization about 80% of the
world’s population in developing countries depends essentially on
plants for their primary health care (WHO, 2002)., analysis of variance; OB,
take inhibitor
ax: þ55 48 3721 9672.
der the Elsevier OA license.Moreover, the knowledge of medicinal plants often represents
the only therapeutic option for many communities and ethnic
groups in poor countries. However, few plants have been scientiﬁ-
cally studied for the assessment of their quality, safety and efﬁcacy
(Calixto, 2005).
Rosemary, Rosmarinus ofﬁcinalis L. (Labiatae), is among a variety
of plants used in folk medicine worldwide for the ﬁrst health care.
It is an evergreen perennial shrub native native to Asia Minor and
southern Europe; today it has been cultivated in many parts of the
world (Al-Sereiti et al., 1999; Heinrich et al., 2006). Several reports
in the literature have shown the ethnopharmacological uses of
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physical and mental fatigue, improvement of memory and treat-
ment of nervous agitation, hysteria and depression, among other
applications (Duke, 2000; Heinrich et al., 2006).
Preclinical studies have demonstrated that the extract of this
plant exerts a number of pharmacological activities, such as
hepatoprotective (Sotelo-Fe´lix et al., 2002), antibacterial (Del
Campo et al., 2000), diuretic (Haloui et al., 2000), antidiabetic
(Bakirel et al., 2008), antioxidant (Bakirel et al., 2008), antinoci-
ceptive (Gonza´lez-Trujano et al., 2007) and anti-inﬂammatory
(Beninca´ et al., 2011). We have shown that Rosmarinus ofﬁcinalis
hydroalcoholic extract (ROHE) produces an antidepressant-like
effect in the forced swim test and tail suspension test, predictive
tests of antidepressant activity, by a mechanism dependent on the
interaction with the monoaminergic systems (Machado et al.,
2009). However, the ability of Rosmarinus ofﬁcinalis to reverse
depressive-like behavior induced by a model of depression that
mimics several symptoms observed in depressed patients was not
reported in the literature.
The olfactory bulbectomy (OB) is an animal model of depression
characterized by the bilateral destruction of the olfactory bulbs,
which produces behavioral, neurochemical and neuroendocrinolo-
gical changes that resemble some of the symptoms observed in
depressed individuals (Kelly et al., 1997; Leonard, 1984; Song and
Leonard, 2005). Therefore, OB provides a good model for studying
antidepressant drugs and also may provide neurochemical and
neuroanatomical data that are relevant to understand the biologi-
cal substrates of emotion and the causes of depression in humans
(Jesberger and Richardson, 1988). It is also important to mention
that OB is one of the few models of depression that mimics the
slow onset of antidepressant action reported in clinical studies,
since the efﬁcacy of antidepressants in this model is evident almost
exclusively after 14 days of treatment (O’Neil and Moore, 2003).
Hyperactivity response, the major behavioral change observed in
this model, can be reversed by chronic treatments with antide-
pressants (Kelly et al., 1997; Leonard and Tuite, 1981; Van Riezen
and Leonard, 1990). Additionally, OB causes different signs of
anhedonia, as well as cognitive deﬁcits (Harkin et al., 2003; Kelly
et al., 1997; Song and Leonard, 2005).
OB in rodents has been also associated with biochemical altera-
tions, including a reduction in the brain levels of monoamine
neurotransmitters serotonin and norepinephrine (Kelly et al., 1997;
Lumia et al., 1992; Song and Leonard, 2005), serum glucose level
alterations (Montilla et al., 1984; Perassi et al., 1975), and cholinergic
dysfunction (Moriguchi et al., 2006; Nakajima et al., 2007).
Therefore, this study was aimed at investigating the effects of
chronic administration of ROHE in behavioral and biochemical
alterations induced by OB in mice.2. Materials and methods
2.1. Plant material and preparation of ROHE
Stems and leaves of Rosmarinus ofﬁcinalis (Labiatae) were
collected in Santo Amaro da Imperatriz, Santa Catarina, Brazil,
and identiﬁed by Dr. Daniel Falkenberg, from Department of
Botany, Federal University of Santa Catarina. A voucher specimen
(Excicata number 34918) was deposited in the Herbarium of the
Department of Botany, Federal University of Santa Catarina,
Brazil. The preparation of extract, dried aerial parts of Rosmarinus
ofﬁcinalis (600 g) was submitted to maceration in ethanol (96%)
during ﬁfteen days at room temperature (2572 1C). Thereafter,
the extract was ﬁltered and then concentrated under reduced
pressure (at approximately 60 1C). The maceration was repeated
three times. After removing the solvent by lyophilization, thisprocedure gave 61 g of a green solid and dry hydroalcoholic crude
extract (10.2% w/w yield).The ROHE was obtained according to
the methodology described by Machado et al. (2009). The extract
was kept in closed bottle at 4 1C in a refrigerator for further use.
2.2. HPLC proﬁle of ROHE
The liquid chromatography (HPLC) proﬁle of ROHE was per-
formed according to Beninca´ et al. (2011). Carnosol used as
standard for quantiﬁcation was obtained according to Beninca´
et al. (2011). The triterpenes betulinic acid, oleanolic acid, ursolic
acid and rosmarinic acid (Sigma-Aldrich, Steinheim, Germany)
were also used as standards.
2.3. Animals
Female Swiss mice (50–55 day old, weighing 35–40 g) were
used for this study and maintained at constant room temperature
(2171 1C) with free access to water and food, under a 12:12 h
light:dark cycle (lights on at 07:00 h). Mice were allowed to
acclimatize to the holding room for 24 h before the behavioral
procedure (N¼9–11 animals per group). All experiments were
carried out between 9:00 and 16:00 h. The procedures in this
study were performed in accordance with the National Institute
of Health Guide for the Care and Use of Laboratory Animals and
approved by the Ethics Committee of the Institution. All efforts
were made to minimize animals suffering and to reduce the
number of animals used in the experiments.
2.4. Drugs and treatment
ROHE (10–300 mg/kg, p.o.) and the antidepressant ﬂuoxetine
(10 mg/kg, p.o., Sigma Chemical Company, St. Louis, MO, U.S.A.)
were dissolved in distillated water and given once a day via oral
route (p.o.) by gavage over a period of 14 days (in a constant
volume of 10 mL/kg body weight) to mice. Fluoxetine, used here as
a positive control, was administered at a dose previously shown to
cause antidepressant-like effects (Machado et al., 2009). The
dissolution of ROHE was freshly done from the lyophilized power
immediately before its administration by gavage. Controls received
an identical volume of distilled water (vehicle).The administration
schedule and the doses of ROHE were chosen on the basis of
experiments previously performed in our laboratory (Machado
et al., 2009).
After 14 post-operative days (recovery period), mice were
assigned to the following groups:
(I) SHAM-operated/treated with distilled water for 14 days
(SHAM/vehicle) as the control group, (II) SHAM-operated/treated
with extract for 14 days (SHAM/extract); (III) SHAM-operated/treated
with ﬂuoxetine for 14 days (SHAM/ﬂuoxetine); (IV) bulbectomized
mice treatedwith distilled water for 14 days (bulbectomized/vehicle);
(V) bulbectomized mice treated with extract for 14 days (bulbecto-
mized/extract); (VI) bulbectomized mice treated with ﬂuoxetine for
14 days (bulbectomized/ﬂuoxetine).
2.5. Bilateral olfactory bulbectomy (OB) surgery
After a 2-week acclimatization period, OB was performed
according to the procedure described by Leonard and Tuite (1981).
Brieﬂy, mice were anesthetized with xylazin (20 mg/kg; Virbac&,
Brazil) in combination with ketamine (100 mg/kg; Virbac&, Brazil),
diluted in saline (0.9% NaCl) administered intraperitoneally (i.p.);
10 mL/kg body weight. The skull covering the olfactory bulbs was
exposed by skin incision and two burr holes were drilled using a
dentist drill. The olfactory bulbs were bilaterally aspirated using a
blunt hypodermic needle (1.0–1.2 cm long and with a rounded tip of
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not to cause any damage to the frontal cortex).
Finally, the burr hole was ﬁlled with acrylic resin, in order to
avoid bleeding and contamination at the surgical site. SHAM-
operations were performed in the same way, but the olfactory
bulbs were left intact. After being submitted to the surgical
procedure, all animals were allowed to recover in a post-operative
cage (maintained at 24 1C) for 3 h. After this time period, mice
were returned to their home cage. This technique was adapted
from previous studies (Leonard, 1984; Leonard and Tuite, 1981;
Van Riezen and Leonard, 1990; Zueger et al., 2005).
At the end of the experiments, all animals were sacriﬁced and
the presence of the lesions was veriﬁed. The bulbectomized
animals that showed incomplete removal of the olfactory bulbs
or damage to other brain areas (less than 15% of the total) were
excluded from subsequent analysis following the criteria pre-
viously described (Jarosik et al., 2007; Kelly et al., 1997).
A 14 day post-surgery period time interval was considered to
be sufﬁcient to guarantee an appropriate recovery of the animals,
as indicated in literature studies (Jarosik et al., 2007; van Riezen
and Leonard, 1990; Zueger et al., 2005).
As depicted in Fig. 1, fourteen days after surgery (1–141 Day,
recovery period), drug treatment was started and continued for a
period of 14 days (15–281 Day, treatment period).2.6. Behavioral tests
One day before surgery, locomotor activity and exploratory
behavior was analyzed using the open-ﬁeld. Behavioral changes
after OB and/or chronic treatment with ROHE were examined by
testing locomotor activity and exploratory behavior in the open-
ﬁeld 4 weeks after OB and 2 weeks after the beginning of chronic
drug treatment (Fig. 1). All tests were carried out during the light
phase of the light/dark cycle. Light intensity was approximatelyFig. 1. Schematic representation of the experimental protocol with the treatment per
decapitation 6 h after the end of the behavioral testing on day 33. Blood samples were
80 1C for subsequent biochemical analysis (Panel B). (OFT: open-ﬁeld test, NOT: novel
Test WM: test session of the water maze).200 lx. On the ﬁrst test day (day 29 of the experiment), 24 h after
the last drug treatment, mice were submitted to the open-ﬁeld.
After two hours (time period previously shown to cause no
behavioral interference), mice were submitted to the splash test
in order to investigate anhedonic behavior (Moretti et al., 2012).
On the second test day (day 30 of the experiment), 48 h after the
last drug treatment, mice underwent the novel object test. On day
31, 72 h after the last drug treatment, mice were submitted to the
novel cage test. On day 32, 96 h after the last drug treatment,
mice were subject to training sessions of the water maze task and
on day 33, 120 h after the last drug treatment, mice were subject
to a test session of the water maze task.
2.6.1. Open-ﬁeld test
The open-ﬁeld test was used to investigate locomotor activity
and exploratory behavior, since locomotor hyperactivity is the
key behavioral feature of bulbectomized rodents. Mice were
individually placed in a wooden box (406050 cm3) with the
ﬂoor divided into 12 squares. Number of crossings (number of
squares crossed by the animal with the four paws) was used to
evaluate locomotor activity whereas number of rearings (number
of times the mice stood on its hind legs or vertical exploratory
activity) to assess the exploratory behavior (Machado et al., 2009;
van Riezen and Leonard, 1990; Zueger et al., 2005). All the
parameters were registered in a 6-min period.
The apparatus was cleaned with a solution of ethanol 10%
between tests in order to remove animal odors or clues.
2.6.2. Splash test
The splash test was adapted from Yalcin et al. (2005). This test
evaluates grooming behavior, deﬁned as cleaning of the fur
by licking or scratching, after the vaporization of 10% sucrose
solution on the dorsal coat of mice. The viscosity of the sucrose
solution dirties the coat and animals initiate grooming behavior,iod with ROHE and behavioral tests period (Panel A). The animals were killed by
collected and hippocampus and frontal cortex dissected, then stored in a freezer at
object test, NCT: novel cage test, Trials WM: training session of the water maze and
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(idle time between spray and initiation of grooming) and decr-
eased time spent grooming (d’Audiffret et al., 2010). The groom-
ing behavior included nose/face grooming (along the snout), head
washing (semicircular movements over the top of the head and
behind the ears), and body grooming (body fur licking) (Kalueff
and Tuohimaa, 2004). Latency and time spent grooming were
recorded for 5 min.
2.6.3. Novel object test
The novel object test was performed in the same arena and
test conditions employed for the open-ﬁeld test, in order to
evaluate the exploratory behavior of mice when exposed to an
unknown object (50 mL Falcon tube stylized with colorful stripes,
placed top down). In this experimental protocol, the novel object
was placed in the center of the open-ﬁeld (wooden box measuring
40 6050 cm3, with a central area measuring 19.518.5 cm2).
The area that surrounds this central part is referred to as the
peripheral area. The time spent exploring the novel object, as
well as number of rearings in the central area of the apparatus,
was recorded for 6 min (adapted from Zueger et al., 2005). The
apparatus was cleaned with a solution of ethanol 10% between
tests in order to remove animal odors.
2.6.4. Novel cage test
To investigate the exploratory behavior of the animal in a novel
environment, a circular blue plastic arena (d¼44 cm, h¼22 cm)
with the ﬂoor divided into 9 parts was used. The animals were
placed in the center of this apparatus in the beginning of the test.
The number of crossings and rearings was registered for 6 min
(adapted protocol from Zueger et al., 2005). After each test, the
apparatus was sprayed with a solution of ethanol 10% and wiped
thoroughly to clean and eliminate the residual odor.
2.6.5. Water maze test-memory reference task
The water maze task was performed in a circular swimming
pool similar to that described by Morris et al. (1982). The pool
was made of black painted ﬁberglass, 97 cm in diameter and
60 cm in height. For the tests, the tank was ﬁlled with water
maintained at 23þ2 oC. The target platform (1010 cm2) was
made of transparent Plexiglas and it was submerged 1–1.5 cm
beneath the surface of the water. Starting points for animals were
marked on the outside of the pool as north (N), south (S), east
(E) and west (W). Four distant visual cues (5555 cm2) were
placed on the walls of the water maze room. They were all
positioned with the lower edge 30 cm above the upper edge of the
water tank and in the standard setting, the position of each
symbol marked the midpoint of the perimeter of a quadrant
(circle¼NE quadrant, square¼SE quadrant, cross¼SW quadrant,
and diamond¼NW quadrant). The apparatus was located in a
room with indirect incandescent illumination. A monitor and a
video-recording system were installed in an adjacent room. The
experiments were video-taped and the scores for latency of
escape from the starting point to the platform during the training
sessions and the time spent in the correct quadrant during the
probe test session were later measured through the ANY-mazeTM
video tracking system (Stoelting Co., Wood Dale IL, USA).
Mice were submitted to a spatial reference memory version of
the water maze using a protocol that was similar to one described
previously (Prediger et al., 2007). The training session consisted of
ten consecutive trials during which the animals were left in the
tank facing the wall and then allowed to swim freely to the
submerged platform. The platform was located in a constant
position (middle of the southwest quadrant), equidistant from
the center and the wall of the pool. If the animal did not ﬁnd theplatform during a period of 60 s, it was gently guided to it. The
animal was allowed to remain on the platform for 10 s after
escaping to it and was then removed from the tank for 20 s before
being placed at the next starting point in the tank. This procedure
was repeated ten times, with the starting points (the axis of one
imaginary quadrant) varying in a pseudo-randomized manner.
The test session was carried out 24 h later and consisted of a
single probe trial where the platform was removed from the pool
and each mouse was allowed to swim for 60 s in the maze. The
time spent in the correct quadrant (i.e. where the platform was
located on the training session) was recorded and the percentage
of the total time was analyzed.2.7. Biochemical analysis
Blood collection was performed by decapitation 6 h after the
last behavioral test. Animals fasted for 8 h before blood collection
in order to cause no interference in the analysis of serum glucose.
The blood samples were collected and allowed to coagulate at
room temperature for 30 min and were subsequently centrifuged
at 3000g for 10 min. Serum was removed and stored at 80 1C
until analysis.
For AChE determination, hippocampus and frontal cortex were
homogenized in potassium phosphate buffer (0.1 M, pH 8). The
homogenates were centrifuged at 2300g for 15 min and the
supernatant was separated and stored at 80 1C until analysis.2.7.1. Serum glucose determination
The serum glucose levels were measured by the method des-
cribed by Barham and Trinder (1972), using the commercial kit
Kovalent, by enzymatic colorimetric method Glucose GOD-PAP. The
principle of this method is based on the determination of glucose
after enzymatic oxidation by glucose oxidase. The colorimetric
indicator is quinonimine, which is generated from 4-aminoantipi-
pirina and phenol by hydrogen peroxide under the catalytic action
of peroxidase (Trinder’s reaction).2.7.2. Determination of AChE activity
AChE activity was measured by the method described by
Ellman et al. (1961), using acetylthiocholine iodide as a substrate
in homogenates of hippocampus and cerebral cortex. Each sample
was assayed in triplicate. The rate of hydrolysis of acetylthiocho-
line iodide was measured at 412 nm through the release of the
thiol compound, which reacts with DTNB producing the colored
product thionitrobenzoic acid.2.7.3. Protein determination
The protein content in hippocampal and frontal cortex homo-
genate samples was determined using the method of Bradford
(1976), using bovine serum albumin as a standard.2.8. Statistical analysis
Comparisons between the pre-operative and post-operative
periods (SHAM X OB groups) and training session of water maze
task were performed by repeated one-way-measures analysis of
variance (ANOVA), one-way-ANOVA for test session of water
maze task and two-way ANOVA for study of the post-treatment
period (SHAM X OB-vehicle treatment and SHAM X OB-extract
or ﬂuoxetine treatment groups) followed by Duncan test when
appropriate. All data are expressed as mean7standard error of
the mean (S.E.M.). Differences with Po0.05 were considered
statistically signiﬁcant.
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3.1. Phytochemical analysis and high-performance liquid
chromatographic proﬁle (HPLC)
As shown in Fig. 2 the major compounds identiﬁed in ROHE
were carnosol, ursolic acid, oleanolic acid, betulinic acid and
rosmarinic acid. Ursolic acid (15.71%) and carnosol (10.03%) are
the compounds present at higher concentrations in ROHE. Although
at lower concentrations, the terpenes betulinic acid (6.21%) and
oleanolic acid (5.73%), as well as the phenolic acid, rosmarinic acid
(5.99%) was also found in ROHE.
3.2. Effect of chronic treatment with ROHE on OB-induced locomotor
and exploratory hyperactivity in the open-ﬁeld test
The results depicted in Fig. 3A and B show that bulbectomized
mice presented an increased number of crossing and rearings in
the open-ﬁeld test, as compared to control group (SHAM-vehicle),
indicating that OB induced an enhancement of locomotor and
exploratory activities. However, the bulbectomized mice sub-
mitted to chronic p.o. treatment with extract (10–300 mg/kg)
and ﬂuoxetine (10 mg/kg) demonstrated a signiﬁcant decrease in
locomotor activity and exploratory behavior as compared to the
OB-vehicle. The two-way ANOVA revealed a signiﬁcant main
effect of OB [F(1,91)¼37.53, Po0.01] and treatment X OB inter-
action [F(4,91)¼3.99, Po0.01], but no signiﬁcant effect of the
treatment [F(4,91)¼1.08, P¼0.37] in locomotor activity in the0.00
0.25
0.50
0.75
1.60
5 10 15 20 25
Minutes
A
U
Fig. 2. Chromatographic proﬁles (HPLC) of crude extract from Rosmarinus ofﬁci-
nalis L. Peaks represent rosmarinic acid (1), carnosol (2), betulinic acid (3),
oleanolic acid (4), and ursolic acid (5).
Fig. 3. Effect of the chronic treatment of mice (14 day) with ROHE (10–300 mg/kg, p.o.
(panel B) in bulbectomized mice in the open-ﬁeld test. Each column represents the mean
þPo0.05, þþPo0.01 when compared with OB-vehicle group. Results were analyzed byopen-ﬁeld test. The two-way ANOVA also revealed a signiﬁcant
effect of OB [F(1,91)¼33.96, Po0.01], treatment X OB interac-
tion: [F(4,91)¼6.82, Po0.01], but no signiﬁcant effect of the
treatment [F(4,91)¼1.36, P¼0.25] in exploratory activity in the
open-ﬁeld test.3.3. Effect of chronic treatment with ROHE on OB-induced
hyperactivity as assessed with the novel object and novel cage tests
Fig. 4 shows that OB caused a signiﬁcant increased time spent
exploring the novel object and an increased number of rearings in
the central area of the apparatus as compared to the control group
(SHAM-vehicle) (Fig. 4A and B, respectively). These results indi-
cate an OB-induced hyperactivity in the novel object test.
Furthermore, chronic treatment with ROHE (10–300 mg/kg, p.o.)
and ﬂuoxetine (10 mg/kg, p.o.) in bulbectomized mice caused
a reversal of the hyperactivity induced by novelty, since it
decreased the time spent exploring the novel object and the
number of rearings in the central area when compared with the
OB-vehicle group (Fig. 4A and B). The two-way ANOVA revealed a
signiﬁcant effect of OB [F(1,90)¼11.73, Po0.01] and treatment X
OB interaction [F(4,90)¼3.06, Po0.05], but not of treatment
[F(4,90)¼0.90, P¼0.46] in the time exploring the novel object.
Regarding the number of rearings around the object, a signiﬁcant
effect of OB [F(1,90)¼9.65, Po0.01] and treatment X OB interac-
tion [F(4,90)¼3.21, Po0.05], but not of treatment [F(4,90)¼1.64,
P¼0.17] was observed.
As shown also in Fig. 4C–D, bulbectomized mice showed
locomotor and exploratory hyperactivity induced by the novel
environment when compared to SHAM-vehicle group (147.5% and
187.0% of increase, respectively) in the novel cage test. However,
the bulbectomized mice submitted to chronic treatment with
ROHE (10–300 mg/kg, p.o.) and ﬂuoxetine (10 mg/kg, p.o.)
demonstrated a signiﬁcant decrease in locomotor activity and
exploratory behavior as compared to the OB-vehicle. The two-
way ANOVA revealed a signiﬁcant effect of OB [F(1,90)¼26.61,
Po0.01], treatment X OB interaction:[F(4,90)¼4.60, Po0.01], but
no signiﬁcant main effect of treatment [F(4,90)¼0.61, P¼0.65] in
the locomotor activity in the novel cage test. The two-way ANOVA
also revealed a signiﬁcant main effect of OB [F(1,90)¼32.03,
Po0.01], treatment X OB interaction [F(4,90)¼3.71, Po0.01],
but no signiﬁcant effect of treatment [F(4,90)¼1.14, P¼0.343] in
the exploratory activity in the novel cage test.) and ﬂuoxetine (10 mg/kg, p.o.) on the number of crossings (panel A) and rearings
þS.E.M. of 9–11 animals. **Po0.01 as compared to control group (SHAM-vehicle);
two-way ANOVA, followed by Duncan’s multiple range post-hoc test.
Fig. 4. Effect of chronic treatment of mice (14 day) with hydroalcoholic extract of Rosmarinus ofﬁcinalis (10–300 mg/kg, p.o.) and ﬂuoxetine (10 mg/kg, p.o.), on the
exploratory activity of bulbectomized mice in the novel object test and novel cage test. The exploratory behavior was assessed monitoring the time spent exploring the
novel object (panel A) and the number of rearing responses in the central area of the open-ﬁeld (panel B) in the novel object test; and the number of crossings (panel C) and
rearings (panel D) of bulbectomized mice in the novel cage test. Each column represents the meanþS.E.M. of 9–11 animals. *Po0.05, **Po0.01 compared with the control
group (SHAM-vehicle) and þPo0.05, þþPo0.01 when compared with OB-vehicle group. Results were analyzed by two-way ANOVA, followed by Duncan’s multiple range
post-hoc test.
Fig. 5. Effect of chronic treatment mice (14 day) with ROHE (10–300 mg/kg, p.o.) and ﬂuoxetine (10 mg/kg, p.o.), in bulbectomized mice in the splash test. The anhedonic
behavior of bulbectomized mice was analyzed through latency for initiation of grooming behavior (panel A) and time spent grooming (panel B). Each column represents
the meanþS.E.M. (n¼9–11). **Po0.01 compared with the control group (SHAM-vehicle); þPo0.05, þþPo0.01 when compared with OB-vehicle group. Results were
analyzed by two-way-ANOVA, followed by Duncan’s post-hoc test.
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anhedonic-like behavior assessed by the splash test
The effects of chronic treatment with ROHE in the anhedonic-
like behavior induced by OB were inferred through the latency
and time spent grooming in the splash test, as shown in Fig. 5A
and B, respectively. The results show an increased latency(idle time between spray and initiation of grooming) and
decreased time spent grooming (anhedonic-like behavior) in
bulbectomized mice. Noteworthy, chronic p.o. treatment with
extract (10–300 mg/kg) or ﬂuoxetine (10 mg/kg) signiﬁcantly
reversed the increased latency (Fig. 5A) and the decreased time
spent grooming (Fig. 5B) elicited by OB. These results indicated
that ROHE and ﬂuoxetine were able to abolish the anhedonic-like
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main effect of OB [F(1,94)¼20.48, Po0.01] and signiﬁcant treat-
ment X OB interaction [F(4,94)¼2.96, Po0.05], but no signiﬁcant
main effect of treatment [F(4,94)¼2.00, P¼0.10] in the latency to
exhibit grooming behavior. A two-way ANOVA also revealed a
signiﬁcant main effect of OB [F(1,94)¼4.23, Po0.05] and treat-
ment [F(4,94)¼6.64, Po0.01] as well as treatment X OB interac-
tion [F(4,94)¼4.10, Po0.01] in the time spent grooming.3.5. Effect of chronic treatment with ROHE in the cognitive
performance of SHAM and bulbectomized mice in the water maze
task
We tested the ability of SHAM-operated and bulbectomized
mice to acquire (training session) and retrieve (test session)
spatial information in the water maze paradigm as indicative of
learning and memory functions. Firstly, to rule out a possible
per se effect of ROHE tested in the spatial learning and memory of
mice, additional groups of mice were evaluated in the water maze
331days after surgery and after the repeated administration
(14 days) of ROHE (10, 100 and 300 mg/kg, p.o.) or ﬂuoxetine
(10 mg/kg, p.o.). The results illustrated in Fig. 6A and B suggestFig. 6. Effects of chronic administration (14 day) with ROHE (10–300 mg/kg) or
ﬂuoxetine (10 mg/kg) on the spatial learning and memory of SHAM-operated mice
evaluated in the water maze task (Panels 6A and 6B). Data are presented as
meansþS.E.M. latency, in seconds, for escape to a submerged platform (6A) (n¼9–
11 animals in each group) and % time in the correct quadrant (6B). The probe test
session was performed 24 h after the training trials. Data are presented as
meansþS.E.M. of the time spent in the correct quadrant.that the treatment with ROHE did not interfere, at least at the
present doses, with the spatial learning and memory of the
animals, since no alterations in the escape latency (training
session) were observed. A one-way ANOVA with repeated mea-
sures revealed no signiﬁcant effect of treatment in the escape
latencies during the training trials [F(4,45)¼2.75, P¼0.39]
(Fig. 6A). Moreover, a one-way ANOVA revealed no signiﬁcant
effect of treatment in time spent in the correct quadrant in test
session [F(4,45)¼1.89, P¼0.13] (Fig. 6B).
As can be seen from Fig. 7A, OB resulted in a signiﬁcant decline
in spatial learning, as indicated by longer latencies to ﬁnd the
platform [F(1,18)¼8.33, Po0.05]. Subsequent Duncan post-hoc
tests indicated that SHAM/vehicle mice learned quicker than
bulbectomized mice, since although both groups displayed simi-
lar ﬁnal escape latencies to ﬁnd the platform, the learning curve
of bulbectomized mice was clearly offset to the right, i.e. they
needed a greater number of trials to satisfactorily acquire the
spatial information (Fig. 7A). The one-way ANOVA revealed no
signiﬁcant effect of OB in time spent in the correct quadrant
(test session) [F(1,18)¼0.06, P¼0.81], as observed in the water
maze (Fig. 7B).
Moreover, repeated administration (14 day) by p.o. route of
ROHE (10, 100 and 300 mg/kg) or ﬂuoxetine (10 mg/kg) did not
promote any signiﬁcant effect on the spatial learning [F(4,48)¼0.36;
p¼0.83] and memory [F(4,48)¼0.38; p¼0.81] of bulbectomized
mice (Fig. 7C and D).3.6. Effect of chronic treatment with ROHE on the serum glucose
level in bulbectomized animals
The results depicted in Fig. 8A show a decreased serum glucose
level in bulbectomized mice as compared with the control group
(SHAM-vehicle). This effect was abolished by p.o. treatment with
ROHE (10 mg/kg), but not by ﬂuoxetine (10 mg/kg). A two-way
ANOVA indicated a signiﬁcant effect of treatment X OB interac-
tion [F(2,46)¼4.11, Po0.05], but not of OB[F(1,46)¼1.57,
P¼0.21] and treatment [F(2,46)¼0.20, P¼0.81].3.7. Effect of chronic treatment with ROHE on cerebrocortical and
hippocampal AChE activity in bulbectomized mice
Fig. 8 also shows the effect of chronic p.o. administration of
ROHE (10 mg/kg) and ﬂuoxetine (10 mg/kg) on the activity of
the enzyme AChE in the cerebral cortex (Fig. 8B) and hippocam-
pus (Fig. 8C) of bulbectomized animals. As demonstrated in
Fig. 8B, the activity of AChE in the frontal cortex was not
changed in the group of bulbectomized mice treated with ROHE
as compared with the control (SHAM-vehicle) and with BO-
vehicle groups. However, as shown in Fig. 8B, the activity of
AChE in the frontal cortex was lower in the group of bulbecto-
mized mice treated with ﬂuoxetine (10 mg/kg, p.o.) as compared
with the bulbectomized/vehicle group. A two-way ANOVA
revealed a signiﬁcant effect of treatment X OB interaction
[F(2,38)¼3.49, Po0.05], but not of OB [F(1,38)¼2.29, P¼0.13]
and treatment [F(2,38)¼1.91, P¼0.16] in the activity of AChE in
the frontal cortex. However, Fig. 8C shows a signiﬁcant increase
on hippocampal AChE activity in bulbectomized/vehicle group,
as compared with control group (SHAM-vehicle), an effect
reversed by ROHE (10 mg/kg, p.o.) and ﬂuoxetine (10 mg/kg,
p.o.). A two-way ANOVA revealed a signiﬁcant main effect of OB
[F(1,38)¼4.28, Po0.05], treatment [F(2,38)¼6.19, Po0.01] and
treatment X OB interaction [F(2,38)¼3.96, Po0.05] on the
activity of AChE in the hippocampus.
Fig. 7. Effects of chronic administration (14 day) with ROHE (10–300 mg/kg) or ﬂuoxetine (10 mg/kg) on the spatial learning and memory of olfactory bulbectomized mice
evaluated in the water maze task. Training trials were carried out on day 32 after OB. Data are presented as meansþS.E.M. latency, in seconds, for escape to a submerged
platform (A,C) (n¼9–11 animals in each group). The probe test session was performed 24 h after the training trials. Data are presented as meansþS.E.M. of the time spent
in the correct quadrant (B,D). *Po0.05 compared to the ﬁrst trial of the same group (Duncan post-hoc test).
Fig. 8. Effect of the chronic treatment of mice (14 day) with ROHE (10 mg/kg, p.o.) and ﬂuoxetine (10 mg/kg, p.o.) on serum glucose level (expressed as mg/dl) (panel A)
and on AChE activity in frontal cortex (panel B) and hippocampus (panel C) of bulbectomized mice. Enzyme activity was expressed as nmol/min/mg protein. Each column
represents the meanþS.E.M. of 7–9 animals. *Po0.05, **Po0.01 compared with the control group (SHAM-vehicle) and þPo0.05, þþPo0.01 when compared with OB-
vehicle group. Results were analyzed by two-way-ANOVA, followed by Duncan’s post-hoc test.
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To gain a better understanding of the potential antidepressant
of Rosmarinus ofﬁcinalis, this study evaluated the effects of the
extract of this plant in the OB model, since the removal ofolfactory bulbs in rodents result in several behavioral, neuro-
chemical and neuroendocrinological alterations, comparable to
those seen in depressed patients (Kelly et al., 1997; Song and
Leonard, 2005). Indeed, the antidepressant-like effect of ROHE
was ﬁrstly investigated by our group in two behavioral models
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(FST) and tail suspension test (TST) in mice. ROHE produced an
antidepressant-like effect, since the acute treatment of mice with
the extract by p.o. route signiﬁcantly reduced the immobility time
in the FST (100 mg/kg) and TST (10–100 mg/kg). Moreover, the
repeated administration (14 day) of the ROHE by p.o. route also
produced an antidepressant-like effect in the TST (100–300 mg/kg).
However, the behavioral tests with predictive validity are desig-
nated with this terminology because they are based exclusively on
the behavioral effects of drugs used clinically, but do not mimic the
symptoms of disease. In addition, another drawback of these tests
is the fact that they are sensitive to the acute administration of
antidepressants, but the action of classical antidepressants in the
existing therapies can take up to several weeks to show their full
therapeutic effect (Cryan et al., 2002, 2005). Interestingly, the OB
model used in the present study has been suggested to possess a
good face validity with human depressive disorder, especially
agitated depression (Harkin et al., 2003; Kelly et al., 1997;
Romeas et al., 2009).
The behavioral abnormalities induced by OB appear after
2 weeks in rodents; probably because the lesion caused by OB
induces reorganization processes in the limbic and cortical areas
(Jarosik et al., 2007; van Riezen and Leonard, 1990; Zueger et al.,
2005). In the present study bulbectomized mice showed a
signiﬁcant increase in locomotor and exploratory activities in
the open-ﬁeld, novel object and novel cage tests and also an
anhedonic-like behavior. These behavioral alterations are indica-
tive of a depressive-like proﬁle of these animals (Harkin et al.,
2003; Kelly et al., 1997; Zueger et al., 2005). Noteworthy, ROHE,
similarly to the antidepressant ﬂuoxetine, used here as a positive
control, was able to abolish these behavioral alterations.
The hyperactivity in bulbectomized animals is the main altera-
tion reported in literature. Various classes of clinically active
antidepressants abolish the hyperactivity of bulbectomized rodents
in the open-ﬁeld, such as: serotonin reuptake inhibitors-SSRIs
(citalopram, ﬂuoxetine, paroxetine, sertraline, venlafaxine),
noradrenaline reuptake inhibitor—NRI (reboxetine), tricyclic anti-
depressant (amitriptyline, desipramine, imipramine) (Butler and
Leonard, 1990; Connor et al., 2000; Jarosik et al., 2007; Kelly et al.,
1997; Possidente et al., 1996; Rodrı´guez-Gaztelumendi et al., 2009;
Song and Leonard, 2005). Additionally, it was reported that curcu-
min, the active component of Curcuma longa, was able to reverse
hyperactivity induced by OB in rats (Xu et al., 2005).
Furthermore, another relevant behavioral change triggered by
the OB is the increased vulnerability and responsiveness to
environmental stress (Mar et al., 2000; van Riezen and Leonard,
1990). In our investigation, the bulbectomized mice showed
locomotor and exploratory hyperactivity induced by novelty,
indicated by an increase in behavioral reactivity when mice were
submitted to the novel object test (decreased latency for entering
the central arena, increased time spent exploring and increased
rearing responses in the central area where the novel object was
located) and to the novel cage test (increased number of crossings
and rearings in the new environment). These results are in
agreement with literature data that report that the hyperactivity
induced by OB is directly related to a greater reactivity to novel
environments or deﬁcit in habituation to new situations (Mar
et al., 2000; van Riezen and Leonard, 1990; Zueger et al., 2005).
The chronic treatments with ROHE (10–300 mg/kg, p.o.) and
ﬂuoxetine (10 mg/kg) were able to reverse all the OB-induced
behavioral alterations in the novel cage test. These results are in
accordance with the fact that antidepressants such as ﬂuoxetine
and amitriptyline are effective to restore normal responding by
permitting more effective adaptation to novel stimuli in the
bulbectomized rodents (Mar et al., 2000, 2002), reinforcing the
notion that ROHE has an antidepressant -like action.Anhedonia, or hyposensitivity to pleasure, is one of the key
symptoms for a diagnosis of depression (WHO, 1992). In the
present study this behavior was inferred by the decreased
grooming time and increased latency to grooming in the splash
test in bulbectomized mice as compared to those exhibited by
control mice (SHAM). This result is in accordance with some
studies that have shown an anhedonic-like behavior in bulbecto-
mized rats (Romeas et al., 2009; Stock et al., 2000). Noteworthy,
in our study, the anhedonic-like behavior induced by OB was
abolished by ROHE and ﬂuoxetine. This result is in line with the
ability the compounds with antidepressant properties, such as the
classical antidepressants ﬂuoxetine, imipramine and desipramine
(David et al., 2009; Detanico et al., 2009;Yalcin et al., 2005) as
well as Ptychopetalum olacoides Bentham (marapuama) extract
(Piato et al., 2008), which were capable of reversing anhedonic
behavior induced by stress models of depression. Moreover, this
result also reinforces the notion the ROHE has antidepressant
properties.
In accordance with previous studies reporting a reduced
performance of OB rodents in different paradigms used to
investigate learning and memory processes (Harkin et al., 2003;
Kelly et al., 1997; Mucignat-Caretta et al., 2006) our results show
a poor performance of OB compared to SHAM-mice in the spatial
version of the Morris water maze. Interestingly, it was shown in
our study that OB mice needed signiﬁcantly more trials in the
training session to acquire the spatial information, but they
displayed a similar proﬁle to that of SHAM-groups in the test
session (24 h later), demonstrating a selective deﬁcit in spatial
learning in water maze task. Important to note, this results is
opposed to some reports that have demonstrated impairment
of OB in both spatial learning and memory in the water maze.
This discrepancy with early data may be explained by differences
between the protocols utilized to evaluate the spatial learning
and memory in the water maze. In these previous studies, each
mice was given 4 trials per day for 4–5 consecutive days to ﬁnd
the platform (Mucignat-Caretta et al., 2006), while in the current
study each mice was given 10 consecutive trials during the
training session (only 1 day) and the test session occurred 24 h
later, similar to study reported by Prediger et al. (2005). Thus, it is
possible that a training schedule with a higher number of
consecutive trials instead of repeatedly training over a number
of days promotes equivalence in the learning performance for
both strains, which can be observed in the similar pattern of the
escape latencies of the latter training trials.
The Morris water maze is a test of hippocampal function
(Morris et al., 1982) that does not depend upon olfactory cues,
but more on visual cues. A study reported by Van Rijzingen et al.
(1995) showed that two weeks after OB, the Morris maze
performance was severely impaired. However this alteration is a
transient cognitive deﬁcit since the recovery occurs sponta-
neously approximately 6 weeks following surgery. Thus, the
Morris maze performance of OB animals and SHAM- controls
6 weeks after surgery did not show a difference in escape latency
neither during acquisition nor during the probe trial.
In the present study the chronic treatment with ROHE
(10–300 mg/kg, p.o.) or ﬂuoxetine did not abolish the deﬁcit in
spatial learning induced by OB. This model of depression induced
an impairment of learning and memory in the three-panel run-
way task in rats (Yamamoto et al., 1997) and in passive avoidance
task in mice on the 7th and 14th day after the surgery (Hozumi
et al., 2003). The impairment of learning and memory induced by
OB in these tests, on the 14th day was improved by administra-
tion of the cholinesterase inhibitor physostigmine. Additionally,
the ability of several compounds, including curcumin (Xu et al.,
2005), nobiletin (Nakajima et al., 2007) and an active ginseng
metabolite (20(S)-protopanaxadiol) (Xu et al., 2010) to reverse
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down was reported. However, there are few data dealing with the
effects of Rosmarinus ofﬁcinalis on cognitive performance, but it
has a history of usage as cognitive enhancer (Kennedy and
Scholey, 2006). A study by Hosseinzadeh et al. (2004) reported
that the essential oil of Rosmarinus ofﬁcinalis injected intraper-
itoneally to rats 0.5 h before training for 5 consecutive days
improved the intact memory and scopolamine-induced learning
deﬁcits in rats performing the Morris water maze task. A recent
study in an elderly population has reported that this plant when
administered at a low dose caused an improvement on cognitive
function but at a high dose caused an impairing effect (Pengelly
et al., 2012). Moreover, in one study of 144 healthy individuals,
airborne Rosmarinus ofﬁcinalis essential oil signiﬁcantly enhanced
cognitive performance and mood (Moss et al., 2003). These
studies reported that the Rosmarinus ofﬁcinalis is a promising
candidate for the improvement of memory in healthy people or
for the treatment diseases associated with cognitive deﬁcit, an
effect that may be due to, at least in part to its anticholinesterase
properties (Duke, 2007; Ingole et al., 2008; Kennedy and Scholey,
2006; Singh et al., 2011). Regarding the present study, it remains
to be established if a more prolonged treatment with ROHE, as
well as ﬂuoxetine, would be able to abolish the OB-induced
cognitive deﬁcit.
In a second experimental phase of this study, we evaluated
some biochemical parameters that could be changed by OB pro-
cedure, as serum glucose level, and activity of the enzyme AChE in
the hippocampus and frontal cortex. The ability of the ROHE and
ﬂuoxetine (positive control) to blunt some of the alterations
induced by OB on these parameters was also evaluated.
This study showed a decrease in the serum glucose level in
bulbectomized animals, as compared with the control-SHAM,
similarly to results previously reported in the literature (Bello´
and Rummler, 1980; Perassi et al., 1975). Moreover, a recent
study showed that acute hypoglycemia causes depressive-like
behaviors (increased immobility in the forced swim test and
reduced saccharin preference, an indicative of anhedonic-like
behavior) in mice which were prevented by the antidepressants
ﬂuoxetine and desipramine (Park et al., 2012). However, in
present study the chronic treatment with ﬂuoxetine was not able
to alter the reduction of serum glucose level induced by OB.
Interestingly, treatment with ROHE decreased serum glucose
level in SHAM mice, but abolished the decrease on glucose levels
induced by OB, since it was able to restore serum glucose level to
normal. Thus, the effects of ROHE and ﬂuoxetine on serum
glucose level in SHAM and OB mice are quite different. Indeed
literature data have reported that Rosmarinus ofﬁcinalis exerts
notable hypoglycemic or anti-hyperglycemic activity (Abu-Al-
Basal, 2010; Bakirel et al., 2008). Although interesting the effects
of ROHE and ﬂuoxetine on serum glucose level do not seem to be
associated with the behavioral alterations described in our study.
Taking into account the well known implication of the choli-
nergic system with the behavioral alterations elicited by OB
(Moriguchi et al., 2006; Nakajima et al., 2007) and in the patho-
physiology of depression (Dagyt_e et al. 2011), the present study
also dealt with the determination of AChE activity in the hippo-
campus and frontal cortex. AChE is an important constituent of
cholinergic neurotransmission that catalyzes the hydrolysis of
acetylcholine in the synaptic cleft and neuromuscular junctions
(Soreq and Seidman, 2001). Interestingly, in the present study an
increase on AChE activity in the hippocampus, but not in the
frontal cortex, in the bulbectomized mice was reversed by chronic
treatment with ROHE (10 mg/kg) and ﬂuoxetine (10 mg/kg). In line
with this, the in vitro anticholinesterase effect of Rosmarinus
ofﬁcinaliswas reported (Adsersen et al., 2006). Moreover, treatment
with the antidepressant ﬂuoxetine decreased the activity of AChEin human serum and erythrocyte membrane (Mu¨ller et al., 2002).
Our results suggest that an increased hippocampal activity of this
enzyme may be associated with the depressive-like behavior
observed in the bulbectomized mice. Regarding the ability of ROHE
and ﬂuoxetine to reduce the activity of AchE, consequently
increasing acethylcholine levels, we may raise the hypothesis that
this could lead to a desensitization of nicotinic acethylcholine
receptors. Indeed, it has been proposed that a ﬁne balance between
the activation and desensitization of nicotinic receptors is required
to yield relevant antidepressant-like effects (Mineur and Picciotto,
2010). However, in our study an absence of alteration of AChE in
cerebral cortex was observed in olfactory bulbectomized mice, a
result that is similar to a ﬁnding reported by Yamada et al. (2011)
in bulbectomized mice.5. Conclusion
The present study shows that OB mice exhibited hyperactivity
and anhedonic-like behavior associated with an increased hippo-
campal AChE activity, parameters that were abolished by chronic
treatment with ROHE, similar to the effects produced by ﬂuox-
etine. These results suggest that Rosmarinus ofﬁcinalis may be
further investigated as an effective therapeutic alternative for the
treatment of agitated depression associated with anhedonia.Conﬂict of interest
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